Zobrazeno 1 - 8
of 8
pro vyhledávání: '"S. L. Kelley"'
Publikováno v:
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 12(4)
We describe the first systematic survey of pathology laboratories serving Iowans to assess attitudes concerning assistance with cancer research efforts. Previous reports suggested that pathologists are reluctant to loan slides and/or paraffin tissue
Publikováno v:
Transplantation proceedings. 28(2)
Publikováno v:
Transplantation proceedings. 26(2)
Autor:
A J, Matas, P F, Gores, S L, Kelley, M, Bielefield-Skrokov, M, Kinaszczuk, R W, Gruessner, J S, Najarian
Publikováno v:
Clinical transplantation. 8(2 Pt 1)
15-deoxyspergualin (DSG) is a novel immunosuppressant which has been shown to be effective in preventing and treating rejection in animal allo- and xenotransplant models. Preliminary clinical studies suggest that DSG is an effective antirejection age
Autor:
Paul F. Gores, S. L. Kelley, J. J. Lloveras, E. Stephanian, D. E. R. Sutherland, J. S. Najarian
Publikováno v:
Lancet (London, England). 341(8836)
Islet transplantation has been slow to develop as a therapy for type I diabetes mellitus. Conventional immunosuppression does not protect islet allografts from early failure and by current techniques the yield of purified islets from a single pancrea
Autor:
F M, Muggia, S L, Kelley
Publikováno v:
Seminars in oncology. 19(2 Suppl 6)
Teniposide and etoposide are third-generation semi-synthetic derivatives of epipodophyllotoxin. Following the initial clinical introduction of teniposide in the 1970s, investigations focused almost exclusively on its analogue, etoposide, because of i
Publikováno v:
Cancer research. 48(3)
Glutathione transferase (GST) activity and GST isoenzyme composition have been determined for 24 human neoplasms and 6 human tumor cell lines. Substantial activity (40-1010 milliunits/mg protein) was identified in all tumor specimens examined and thr
Publikováno v:
Cancer treatment reports. 70(4)
A trial of droperidol as an antiemetic was undertaken during 48 courses of cisplatin chemotherapy in 31 patients with cancer. The optimal loading dose was 10 mg iv, with a maintenance dose of 4 mg iv every 2 hours for four additional doses. Beyond th